“…Currently, photosensitizers commonly used in clinical PDT belong to a class of chemicals called porphyrinuria, which are limited in use due to their hydrophobicity, lack of targeting, and relatively low ROS production efficiency. , Based on this, photosensitive nanoagents have been widely developed because of their excellent properties such as adjustable optical properties, strong photobleaching resistance, easy target modification, and good biocompatibility . Among them, carbon dots (CDs), as a new type of fluorescent nanomaterials, have become a promising candidate for fluorescence imaging photosensitizers due to their unique valence band, broad excitation spectra, tunable wavelength, and electron/hole pairs that generate singlet oxygen under illumination conditions. , In addition, the unique photochemical properties, superior biocompatibility, easy surface functionalization, and low toxicity of CDs provide favorable conditions for their application in tumor PDT. , As mentioned earlier, excessive GSH in solid tumors can consume oxygen (O 2 ) produced by PDT drugs, and the hypoxic environment of the tumor exacerbates this situation . To achieve a balance between high tumor accumulation efficiency and rapid clearance from the body after treatment, it is necessary to develop a new CDs-based multifunctional nanosystem that not only enhances the cell uptake of photosensitizers but also reduces GSH levels in cancer cells and improves tumor hypoxia.…”